- Title
- Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021
- Creators
- Wesley H. Self - Vanderbilt UniversityMark W. Tenforde - Response BiomedicalJillian P. Rhoads - Vanderbilt UniversityManjusha Gaglani - Texas A&M UniversityAdit A. Ginde - University of Colorado DenverDavid J. Douin - University of Colorado DenverSamantha M. Olson - Response BiomedicalKeipp Talbot - Vanderbilt UniversityJonathan D. Casey - Vanderbilt UniversityNicholas M. Mohr - University of IowaAnne Zepeski - University of IowaTresa McNeal - Texas A&M UniversityShekhar Ghamande - Texas A&M UniversityKevin W. Gibbs - Wake Forest UniversityD. Clark Files - Wake Forest UniversityDavid N. Hager - Johns Hopkins UniversityArber Shchu - Johns Hopkins UniversityMatthew E. Prekker - Hennepin County Medical CenterHeidi L. Erickson - Hennepin County Medical CenterMichelle N. Gong - Yeshiva UniversityAmira Mohamed - Yeshiva UniversityDaniel J. Henning - University of WashingtonJay S. Steingrub - Tufts UniversityIthan D. Peltan - University of UtahCaitlin C. ten Lohuis - Emory UniversityAbhijit Duggal - Cleveland ClinicJennifer G. Wilson - Stanford UniversityAlexandra June Gordon - Stanford UniversityNida Qadir - University of California, Los AngelesSteven Y. Chang - University of California, Los AngelesChristopher Mallow - University of MiamiCarolina Rivas - University of MiamiHilary M. Babcock - Washington University in St. LouisJennie H. Kwon - Washington University in St. LouisMatthew C. Exline - The Ohio State UniversityNatasha Halasa - Vanderbilt UniversityJames D. Chappell - Vanderbilt UniversityAdam S. Lauring - University of Michigan–Ann ArborCarlos G. Grijalva - Vanderbilt UniversityTodd W. Rice - Vanderbilt UniversityIan D. Jones - Vanderbilt UniversityWilliam B. Stubblefield - Vanderbilt UniversityAdrienne Baughman - Vanderbilt UniversityKelsey N. Womack - Vanderbilt UniversityChristopher J. Lindsell - Vanderbilt UniversityKimberly W. Hart - Vanderbilt UniversityYuwei Zhu - Vanderbilt UniversityLisa Mills - Response BiomedicalSandra N. Lester - Response BiomedicalMegan M. Stumpf - Response BiomedicalEric A. Naioti - Response BiomedicalMiwako Kobayashi - Response BiomedicalJennifer R. Verani - Response BiomedicalNatalie J. Thornburg - Response BiomedicalManish M. Patel - Response BiomedicalSamuel M. Brown - University of UtahEmily T. Martin - University of Michigan–Ann ArborArnold S. Monto - University of Michigan–Ann ArborAkram Khan - Oregon Health & Science UniversityCatherine L. Hough - Oregon Health & Science UniversityLaurence W. Busse - Emory UniversityIVY NetworkHayley Beth Gershengorn - Miller School of Medicine
- Publication Details
- MMWR. Morbidity and mortality weekly report, Vol.70(38), pp.1337-1343
- Publisher
- Centers Disease Control & Prevention
- Number of pages
- 7
- Grant note
- Janssen Pharmaceuticals; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc Campbell Alliance/Syneos Health LLC United Therapeutics New York University for service on a DSMB Abbott Labs; Abbott Laboratories Lung LLC Reata Pharmaceuticals Aerpio Pharmaceuticals AbbVie Endpoint LLC Entegrion, Inc DoD; United States Department of Defense Agency for Healthcare Research and Quality (AHRQ); United States Department of Health & Human Services; Agency for Healthcare Research & Quality Avisa Pharma; Dexcel Pharma N23HL153584 / National Institutes of Health (NIH); United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Cumberland Pharmaceuticals, Inc Sanofi EMPACT Precision Medicine bioMerieux Oxford University and Brigham Young University Faron Faron Pharmaceuticals Merck; Merck & Company Department of Defense (DoD); United States Department of Defense AHRQ; United States Department of Health & Human Services; Agency for Healthcare Research & Quality Incyte Corporation institutional fees from Asahi Kasei Pharma Quidel 4D Medical Johnson Johnson; Johnson & Johnson; Johnson & Johnson USA Food and Drug Administration; United States Department of Health & Human Services Marcus Foundation Sedana National Center for Advancing Translational Sciences; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS)
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Pulmonary, Critical Care & Sleep Medicine
- Language
- English
- Resource Type
- Journal article
- PMID
- 34555004
- Record Identifier
- 991031714060502976
Journal article
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021
MMWR. Morbidity and mortality weekly report, Vol.70(38), pp.1337-1343
2021-09-24
PMID: 34555004
Metrics
5 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
Highly Cited Paper
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.104 Virology - General
- 1.104.1353 Coronavirus
- Web Of Science research areas
- Public, Environmental & Occupational Health
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites